Evidence map›Paper›PMID 36526992›Full record

ArticleBMC cancer2022

Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.

Michio Nakamura, Atsushi Ishiguro, Masayoshi Dazai, Yasuyuki Kawamoto, Satoshi Yuki, Susumu Sogabe, Ayumu Hosokawa, Kentaro Sawada, Osamu Muto, Naoki Izawa and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Michio NakamuraDepartment of Gastroenterology, Sapporo City General Hospital, 1-1, Kita 11-jo Nishi 13-chome, Chuo-ku, Sapporo, 060-8648, Japan. michio.nakamura@icloud.com.
Atsushi IshiguroDepartment of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan.
Masayoshi DazaiDepartment of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Satoshi YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Susumu SogabeDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Ayumu HosokawaDepartment of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
Kentaro SawadaDepartment of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.
Osamu MutoDepartment of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan.
Naoki IzawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Koji NakashimaDepartment of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
Yoshiki HorieDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Masataka YagisawaDepartment of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami, Japan.
Shinya KajiuraDepartment of Medical Oncology, Toyama University Hospital, Toyama, Japan.
Takayuki AndoThird Department of Internal Medicine, University of Toyama, Toyama, Japan.
Yosuke MitsuhashiDepartment of Surgery, IMS Sapporo Digestive Disease Center General Hospital, Sapporo, Japan.
Yu SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Yasuka KikuchiDepartment of Diagnostic Imaging, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yoshito KomatsuDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Hokkaido University Hospital · JPNTT Medical Center · JPSt. Marianna University School of Medicine · JPUniversity of Miyazaki Hospital · JPAkita Red Cross Hospital · JPKushiro Rosai Hospital · JPSapporo City General Hospital · JPTeine Keijinkai Hospital · JPToyama University Hospital · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at high risk of bleeding.

methodsIn this multicenter prospective feasibility study conducted at 10 Japanese institutions, patients with active GIC who developed accidental asymptomatic CAT during chemotherapy were recruited. Edoxaban was orally administered once daily without initial parenteral anticoagulant therapy within 3 days after detecting asymptomatic CAT. The primary outcome was the incidence of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) during the first 3 months of edoxaban administration.

resultsOf the 54 patients enrolled from October 2017 to September 2020, one was excluded because of a misdiagnosis of CAT. In the remaining 53 patients, the primary outcome occurred in six patients (11.3%). MB occurred in four patients (7.5%), including gastrointestinal bleeding in three patients and intracranial hemorrhage in one patient. CRNMB occurred in two patients (3.8%), including bleeding from the stoma site and genital bleeding in one patient each. There were no deaths attributable to bleeding, and all patients who experienced MB or CRNMB recovered.

conclusionsThe risk of bleeding after edoxaban without heparin pretreatment was acceptable, demonstrating new treatment options for asymptomatic CAT in patients with GIC.

Indexed as

Gastrointestinal NeoplasmsThrombosisAnticoagulantsEast Asian PeopleFactor Xa InhibitorsFeasibility StudiesHemorrhageHeparinHumansProspective StudiesPyridinesThiazolesAnticoagulantsedoxabanFactor Xa InhibitorsHeparinPyridinesThiazolesBleedingEdoxabanGastrointestinal cancerHeparinThrombosis

Identifiers

PMID36526992
PMCPMC9757916
OpenAlexW4311690982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.